PT Kimia Farma Tbk - Company Profile
Powered by 
All the sales intelligence you need on PT Kimia Farma Tbk in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how PT Kimia Farma Tbk fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with PT Kimia Farma Tbk.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
PT Kimia Farma Tbk (Kimia Farma), a subsidiary of PT Bio Farma, is a pharmaceutical company that manufactures, commercializes, and distributes pharmaceutical products. The company's products include finished drugs, herbal medicines, and cosmetics. It offers products in various categories, including the alimentary system, allergy and immune system, anaesthetics (both local and general), antibiotics, antidotes, and detoxifying agents. Additional categories include cardiovascular and hematopoietic, dermatological, eye and ear, genito-urinary system, hormones, intravenous and other sterile products, metabolism, neuromuscular treatments, other chemotherapeutics, respiratory aids, vitamins, and minerals. Kimia Farma operates a distribution network that supplies its products to pharmacies, hospitals, and medical centers in Asia, Europe, and Africa. The company operates manufacturing plants in Jakarta, Bandung, Semarang, Watudakon, Medan, and West Java, among others. Kimia Farma is headquartered in Jakarta, Indonesia.
Headquarters
Indonesia
Address
Jalan Veteran No. 9, Jakarta, Daerah Khusus Ibukota Jakarta Raya, 10110
Website
www.kimiafarma.co.id
Telephone
62 213 8477709
No of Employees
9,838
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KAEF (JAK)
Revenue (2024)
$560.3M
-7.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
60.2%
(2024 vs 2023)
Market Cap*
$139.6M
Net Profit Margin (2024)
XYZ
57.1%
(2024 vs 2023)
* As of and is in US$
PT Kimia Farma Tbk premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Pharmaceuticals | Magasida |
| Ethical Drugs | Marcks |
| Other | Venus |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In July, the company launched Fentakaf, a domestically developed pain relief injection. |
| 2024 | Contracts/Agreements | In October, the company entered into a collaboration with Yaden International. |
| 2024 | New Products/Services | In June, the company along with WSAudiology SEA launched a hearing aid product Vibe. |
Competitor Comparison
| Key Parameters | PT Kimia Farma Tbk | PT Kalbe Farma Tbk | PT Tempo Scan Pacific Tbk | PT Soho Global Health Tbk | PT Pyridam Farma Tbk |
|---|---|---|---|---|---|
| Headquarters | Indonesia | Indonesia | Indonesia | Indonesia | Indonesia |
| City | Jakarta | Jakarta Pusat | Jakarta | Jakarta | Jakarta Selatan |
| State/Province | Daerah Khusus Ibukota Jakarta Raya | Daerah Khusus Ibukota Jakarta Raya | - | - | Daerah Khusus Ibukota Jakarta Raya |
| No. of Employees | 9,838 | 12,895 | 4,480 | 2,334 | 2,341 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daneswara | Director - Finance, Risk Management and HC | Senior Management | - | - |
| Haki Subakti | General Manager - Marketing & Sales of Pharmaceutical Products | Senior Management | - | - |
| Wisnu Sucahyo | President Director | Senior Management | - | - |
| Yuliana Indriati | Director - Research and Development | Senior Management | - | - |
| Hadi Kardoko | Director - Production & Supply Chain | Senior Management | 2023 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer